EMEA-001207-PIP03-20
Key facts
| Invented name |
Gazyvaro
|
| Active substance |
Obinutuzumab
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0512/2020
|
| PIP number |
EMEA-001207-PIP03-20
|
| Pharmaceutical form(s) |
Concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of glomerulonephritis and nephrotic syndrome
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Roche Registration GmbH
E-mail: info.paediatrics@roche.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|